20 completed, 8 terminated, 3 withdrawn, 1 active not recruiting. 20 Phase 2, 9 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 12, Terminated 6, Withdrawn 2 |
| Phase 1 | 9 | Completed 7, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
Follow Glucagonoma: new trials by email Literature Review of Glucagonoma trials Research Report on Glucagonoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DOTATOC PET/CT for Imaging NET Patients 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT - Neuroendocrine Tumors, Insulinoma | Active not recruiting | British Columbia Cancer Agency | 800 | 2018-07-11 | 2026-05-12 | |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study Distal Pancreatectomy Sealing Using LTW - Pancreatic Tumor, Benign, Pancreatic Neoplasms | Phase 1 | Completed | Laser Tissue Welding, Inc. | 11 | 2018-01-01 | 2022-04-06 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Bortezomib, Panobinostat - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 7 | 2010-09-01 | 2017-12-28 |
| Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors PVA microporous hydrospheres/doxorubicin hydrochloride - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Not applicable | Terminated | Yale University | 13 | 2009-02-01 | 2017-08-25 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
| Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors questionnaire administration, quality-of-life assessment - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Unknown | National Cancer Institute (NCI) | 408 | 2006-10-01 | 2013-10-29 | |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors bevacizumab, 5-fluorouracil, leucovorin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 36 | 2005-06-08 | 2023-05-22 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
Showing 20 of 33. Sign in to see all of them.
Insulinoma (33) · Somatostatinoma (31) · Gastrinoma (27) · Carcinoma, Islet Cell (25) · Vipoma (19) · Adenoma, Islet Cell (13) · Neoplasms (12) · Carcinoma, Medullary (9) · Pancreatic Neoplasms (8) · Pheochromocytoma (7) · Carcinoma, Renal Cell (6) · Appendiceal Neoplasms (5) · Bile Duct Neoplasms (5) · Breast Neoplasms (5)
Adenocarcinoma (33) · Adenoma (33) · Carcinoma (33) · Carcinoma, Neuroendocrine (33) · Digestive System Diseases (33) · Digestive System Neoplasms (33) · Endocrine Gland Neoplasms (33) · Endocrine System Diseases (33) · Neoplasms by Histologic Type (33) · Neoplasms by Site (33) · Neoplasms, Germ Cell and Embryonal (33) · Neoplasms, Glandular and Epithelial (33) · Neuroectodermal Tumors (33) · Pancreatic Diseases (33) · Neuroendocrine Tumors (28)
Capecitabine (4) · Everolimus (4) · Octreotide (4) · Leucovorin (3) · Temozolomide (3) · Bevacizumab (2) · Bortezomib (2) · Fluorouracil (2) · Oxaliplatin (2) · Trastuzumab (2) · vatalanib (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Acetates (1) · Biological Therapy (1)
National Cancer Institute (NCI) (8) · ECOG-ACRIN Cancer Research Group (2) · Eastern Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · Vanderbilt-Ingram Cancer Center (2) · Yale University (2) · Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Delcath Systems Inc. (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · INSYS Therapeutics Inc (1) · Laser Tissue Welding, Inc. (1) · Masonic Cancer Center, University of Minnesota (1)
United States (26) · United Kingdom (2) · Canada (1) · Denmark (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
James Yao (2) · Leonard B. Saltz, MD (2) · Mary Mulcahy, MD (2) · Timothy Hobday (2) · Anthony W. Tolcher, MD (1) · Arkadiusz Dudek, MD (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Francois Benard, MD (1) · Guillaume Cadiot (1) · Jeffrey F. Geschwind, MD (1) · John K. Ramage, MD (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Julian R. Molina, M.D., Ph.D. (1)
PMID 21831734, PMID 22480131, PMID 22722717, PMID 25900182, PMID 25956795, PMID 27020837, PMID 29853660, PMID 36260828, PMID 39863139
N01CM62205 (2), P30CA016672 (2), U01CA076576 (2), U10CA021115 (2), N01CM62202 (1), P30CA014089 (1), R44CA203052 (1), U01CA062461 (1), U01CA062490 (1), U10CA023318 (1), U10CA180820 (1)